Repurposing vancomycin to fight drug-resistant infection in CF
This article was originally published in Start Up
Savara Pharmaceuticals isn’t the first company keen to develop an inhaled version of a well-known antibiotic for treating lung infections in cystic fibrosis patients. But while other companies have developed inhaled forms of antibiotics against the relatively common infectious organism Pseudomonas aeruginosa, Savara is targeting an equally dangerous bug, methicillin-resistant Staphylococcus aureus.
You may also be interested in...
Savara's NanoCluster dry powder aerosol drug delivery platform has potential for local or systemic delivery of a wide variety of drugs. Savara says that since it can precisely tailor its microparticles' sizes, it will improve aerosol efficiency, and thus will be able to deliver two to three times more drug to the lung than competitors' products.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.